713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trialOliver Klein, Bo Gao, Jimmy Bok Yan So et al.|Annals of Oncology|2024Cited by 11
636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudyBenjamin Y. Kong, David Goldstein, Frank Lin et al.|Annals of Oncology|2024Cited by 0